Newron Pharmaceuticals S.p.A. | WebDisclosure

Basculer en Français

10108	Companies
207142	Keywords
137281	Articles
109791	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

BRIEF

published on 03/18/2026 at 07:05, 9 days 21 hours ago

Newron Pharmaceuticals Announces Board Nominee Changes

Board Of Directors Annual General Meeting Newron Pharmaceuticals George Garibaldi Paolo Zocchi
PRESS RELEASE

published on 03/18/2026 at 07:00, 9 days 21 hours ago

Newron announces nominations to its Board of Directors at upcoming Annual General Meeting
Newron Pharmaceuticals S.p.A. announces nominations for new Board members and resignations of current members ahead of its Annual General Meeting. Full agenda to be released on March 24, 2026

Board Of Directors Annual General Meeting Nominations Newron Pharmaceuticals Resignations
BRIEF

published on 02/16/2026 at 17:50, 1 month 11 days ago

Newron Pharmaceuticals Secures EUR 38 Million for Phase III Evenamide Program

Financing Newron Pharmaceuticals Evenamide Phase III Trials Treatment-resistant Schizophrenia
BRIEF

published on 02/16/2026 at 17:50, 1 month 11 days ago

Newron Pharmaceuticals obtient 38 millions d'euros pour son programme de phase III sur l'événamide.

Financement Newron Pharmaceuticals Evenamide Essais De Phase III Schizophrénie Résistante Au Traitement
PRESS RELEASE

published on 02/16/2026 at 17:45, 1 month 11 days ago

Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program
Newron secures up to EUR 38 million from investors for Phase III Evenamide Program, extending cash runway. Company aims to develop evenamide as add-on therapy for treatment-resistant schizophrenia

Financing Schizophrenia Newron Pharmaceuticals Phase III Evenamide Program
BRIEF

published on 02/03/2026 at 07:05, 1 month 24 days ago

Newron Pharmaceuticals Highlights Benefits of Evenamide for Schizophrenia

Clinical Trials Schizophrenia Newron Pharmaceuticals Evenamide Treatment-resistant
BRIEF

published on 02/03/2026 at 07:05, 1 month 24 days ago

Newron Pharmaceuticals met en avant les bienfaits de l'Evenamide pour la schizophrénie

Essais Cliniques Schizophrénie Newron Pharmaceuticals Evenamide Résistant Au Traitement
PRESS RELEASE

published on 02/03/2026 at 07:00, 1 month 24 days ago

Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
Newron Pharmaceuticals S.p.A. announces publication highlighting Evenamide as adjunctive treatment in schizophrenia. Scientific evidence supports unique approach

Schizophrenia Publication Newron Pharmaceuticals Evenamide Adjunctive Treatment
BRIEF

published on 01/07/2026 at 07:05, 2 months 20 days ago

Clinical Trial for Evenamide in Japan Commences

Phase III Trial Newron Pharmaceuticals Evenamide Schizophrenia Treatment EA Pharma
BRIEF

published on 01/07/2026 at 07:05, 2 months 20 days ago

Début d'un essai clinique pour l'événamide au Japon

Newron Pharmaceuticals Evenamide Traitement De La Schizophrénie Essai De Phase III EA Pharma

Accesswire

Published on 03/28/2026 at 01:00, 3 hours 7 minutes ago

Battery X Metals Announces Confidential Submission of Amended Draft Registration Statement with the U.S. Securities and Exchange Commission in Connection with Proposed U.S. National Securities Exchange Initial Public Offering
Published on 03/28/2026 at 00:55, 3 hours 12 minutes ago

Notification of Relevant Change to Significant Shareholder
Published on 03/28/2026 at 00:50, 3 hours 17 minutes ago

"Rise" Selected as NASA Artemis II Moon Mascot
Published on 03/27/2026 at 22:45, 5 hours 22 minutes ago

Caledonia Mining Corporation Plc - Notification of Relevant Change to Significant Shareholder
Published on 03/27/2026 at 22:30, 5 hours 37 minutes ago

Usha Resources Completes Extended Induced Polarization Survey at the Southern Arm Property

View all ACCESSWIRE

EQS Group

Published on 03/28/2026 at 01:42, 2 hours 25 minutes ago

EQS-Adhoc: Raiffeisen Bank International AG: Agreement on the acquisition of Garanti BBVA Group Romania
Published on 03/27/2026 at 21:58, 6 hours 9 minutes ago

Kaufman & Broad SA: Availability of the Universal Registration Document 2025
Published on 03/27/2026 at 21:58, 6 hours 9 minutes ago

Kaufman & Broad SA: Mise à disposition du Document d'Enregistrement Universel 2025
Published on 03/27/2026 at 20:08, 7 hours 59 minutes ago

EQS-Adhoc: CECONOMY AG: Information on the ongoing public takeover process – uncertainty regarding FDI clearance in Austria
Published on 03/27/2026 at 19:30, 8 hours 37 minutes ago

Turning Potential into Reality: Future 500 Ignites Scale-Up Momentum in Europe

Les Echos

Published on 03/27/2026 at 19:06, 9 hours 1 minute ago

Mersen : Déclaration des transactions sur actions propres
Published on 03/27/2026 at 19:06, 9 hours 1 minute ago

Mersen: Disclosure of trading own shares
Published on 03/27/2026 at 18:52, 9 hours 15 minutes ago

Crédit Agricole CIB announces the publication of its 2025 Universal Registration Document
Published on 03/27/2026 at 18:52, 9 hours 15 minutes ago

Crédit Agricole CIB annonce la publication de son Document d’enregistrement universel 2025
Published on 03/27/2026 at 18:40, 9 hours 27 minutes ago

2026 share capital increase reserved for members of the Saint-Gobain Group employee savings plan

View all LES ECHOS COMFI WIRE